<DOC>
	<DOCNO>NCT00005972</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient recurrent refractory small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Recurrent Refractory Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine overall , complete , partial response rate patient recurrent refractory small cell lung cancer treat gemcitabine plus irinotecan . II . Determine overall failure free survival patient treat regimen . III . Determine duration response patient treatment . IV . Evaluate toxicity associate administration treatment patient population . OUTLINE : Patients stratify accord prior response duration ( progression 90 day initial therapy v progression le 90 day initial therapy response initial therapy ) . Patients receive gemcitabine IV 30 minute irinotecan IV 90 minute day 1 8 . Treatment continue every 21 day absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year , every 6 month 2 year , annually 3 year . PROJECTED ACCRUAL : A total 78 patient accrue study 12-18 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm recurrent refractory small cell lung cancer Measurable disease At least 20 mm conventional technique OR At least 10 mm spiral CT scan The following consider measurable : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Abdominal mass confirm followed imaging technique Cystic lesion Tumor lesion situate previously irradiate area Known CNS metastases allow PATIENT CHARACTERISTICS : Age : 18 Performance status : CTC 02 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 2.0 mg/dL Other : Not pregnant nursing Fertile patient must use effective contraception No prior concurrent malignancy past 5 year except curatively treat carcinoma situ cervix , breast , basal cell squamous cell carcinoma skin PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No 1 prior chemotherapy chemoradiotherapy regimen No prior gemcitabine irinotecan Endocrine therapy : Not specify Radiotherapy : No 1 prior chemoradiotherapy regimen At least 2 week since prior cranial radiotherapy CNS metastases No concurrent cranial radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>recurrent small cell lung cancer</keyword>
</DOC>